Publicaciones en colaboración con investigadores/as de Hospital Universitario de la Princesa (30)

2023

  1. SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry

    Clinical and Translational Oncology, Vol. 25, Núm. 3, pp. 768-775

2022

  1. High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial

    The Lancet Oncology, Vol. 23, Núm. 5, pp. 671-681

  2. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts

    JAMA Oncology, Vol. 8, Núm. 3

  3. Reply to Leonard P. Bokhorst and Berdine L. Heesterman's Words of Wisdom re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial. Eur Urol. 2022;82:441

    European Urology

  4. Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

    Nature medicine, Vol. 28, Núm. 4, pp. 752-765

2021

  1. 10-Year Results of a Phase III Randomized Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation in Localized Prostate Cancer

    International journal of radiation oncology, biology, physics, Vol. 111, Núm. 3, pp. S77

  2. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial

    Radiotherapy and Oncology, Vol. 160, pp. 115-119

2020

  1. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies

    Annals of Oncology, Vol. 31, Núm. 9, pp. 1186-1197

  2. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

    Breast, Vol. 54, pp. 286-292

2017

  1. 18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial

    Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441

  2. Critically short telomeres and toxicity of chemotherapy in early breast cancer

    Oncotarget, Vol. 8, Núm. 13, pp. 21472-21482

  3. Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study

    Medicine, Vol. 96, Núm. 52, pp. e9523

  4. Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors

    Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 386-395

  5. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia

    British Journal of Cancer, Vol. 114, Núm. 11, pp. 1191-1198

  2. Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 Trial

    International Journal of Radiation Oncology Biology Physics, Vol. 96, Núm. 2, pp. 341-348

  3. Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: A retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study

    Melanoma Research, Vol. 26, Núm. 3, pp. 278-283

2015

  1. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): A randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 16, Núm. 3, pp. 320-327

2014

  1. Infrastructures, treatment modalities, and workload of radiation oncology departments in Spain with special attention to prostate cancer

    Clinical and Translational Oncology, Vol. 16, Núm. 5, pp. 447-454

  2. Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: Results of the CNIO-BR002 phase I-trial

    Molecular Oncology, Vol. 8, Núm. 8, pp. 1719-1728